Rani Therapeutics Holdings Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RANI Nasdaq 8731 https://www.ranitherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rani Therapeutics Holdings Inc

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript - Mar 21st, 2024 1:45 pm
RANI: 2023 Results - Mar 21st, 2024 11:40 am
Q4 2023 Rani Therapeutics Holdings Inc Earnings Call - Mar 21st, 2024 10:35 am
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update - Mar 20th, 2024 8:05 pm
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - Mar 15th, 2024 8:05 pm
Individual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the company - Mar 12th, 2024 10:06 am
RANI: INITIATION – Realizing Oral Administration of Biologics - Feb 20th, 2024 9:29 am
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - Feb 5th, 2024 1:00 pm
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - Dec 14th, 2023 1:00 pm
What Makes Rani Therapeutics Holdings, Inc. (RANI) a New Buy Stock - Dec 7th, 2023 5:00 pm
Jean-Luc Butel Buys Handful Of Shares In Rani Therapeutics Holdings - Nov 24th, 2023 10:29 am
Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stock - Nov 24th, 2023 10:29 am
Rani Therapeutics Holdings Inc (RANI) Reports Q3 2023 Financial Results and Corporate Developments - Nov 8th, 2023 10:53 pm
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update - Nov 8th, 2023 9:05 pm
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results - Nov 1st, 2023 8:05 pm
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study - Oct 25th, 2023 12:00 pm
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study - Oct 19th, 2023 8:05 pm
Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research - Oct 12th, 2023 8:05 pm
Private companies invested in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) copped the brunt of last week's US$18m market cap decline - Oct 3rd, 2023 11:38 am
Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43) - Sep 18th, 2023 12:00 pm